Antisense & RNAi Therapeutics Market by Technology (Antisense RNA, RNA Interference), Route of Administration (Intra-dermal Injections, Intraperitoneal Injections, Intravenous Injections), Application, End User - Global Forecast 2024-2030

[199 Pages Report] The Antisense & RNAi Therapeutics Market size was estimated at USD 4.43 billion in 2023 and expected to reach USD 5.07 billion in 2024, at a CAGR 14.64% to reach USD 11.54 billion by 2030.

Antisense and RNA interference (RNAi) therapeutics represent a frontier in genetic medicine, targeting and neutralizing specific RNA molecules to silence disease-causing genes and prevent the production of harmful proteins. These therapies address unmet medical conditions, including genetic disorders such as spinal muscular atrophy, oncology through targeted gene silencing of oncogenes, and viral infections by targeting viral RNA. Factors such as the rising prevalence of genetic conditions and cancers and regulatory approvals by competent authorities propel the market growth. However, high development and manufacturing costs and concerns associated with the efficacy of antisense-RNAi-therapeutics pose significant challenges to the market. Increased collaboration between biotech companies and academic institutions, rising awareness about personalized medicine, and innovation for developing refining nanoparticle delivery systems and integrating CRISPR-Cas9 with RNAi are expected to create potential opportunities for the market in the upcoming time.

The global antisense & RNAi therapeutics market is driven by technological advancement and regulatory frameworks across various geographies. In America, the United States leads the antisense and RNA interference (RNAi) therapeutics market, benefiting from substantial R&D investment, a vibrant biotech industry, and supportive regulatory frameworks. Canada also plays a significant role through strong research capabilities and government funding. In the European Union, countries such as Germany, France, and others rely on the European Medicines Agency (EMA) for consistent drug approval standards, benefiting from collaborative research environments. The Middle East is emerging, led by Israel's robust start-up ecosystem, and South Africa is showing potential in Africa through ongoing efforts to boost biotechnology capabilities. In APAC, China is rapidly growing, investing heavily in RNAi technology, and collaborating internationally. Japan, with its sophisticated healthcare system and government support, continues to advance in antisense and RNAi therapeutics. India's market is expanding, driven by its large population and growing biotech investments.

The market dynamics represent an ever-changing landscape of the Antisense & RNAi Therapeutics Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

• Market Drivers
  • Increasing prevalence of genetic disorders worldwide
  • Rise in R&D activities on antisense and RNAi-based therapies
• Market Restraints
  • High cost of manufacturing antisense-RNAi-therapeutics
• Market Opportunities
  • Collaboration between biotech companies and academic institutions accelerates for antisense & RNAi therapeutics research
  • Rising awareness about personalized medicine
• Market Challenges
  • Concerns associated with the efficacy of antisense-RNAi-therapeutics

• Technology: increasing adoption of RNA interference owing to precise genetic targeting

  RNA interference represents a powerful method for gene silencing, crucial for various therapeutic applications. Advanced research and developments make RNAi a significant focus area. miRNA therapeutics target multiple genes simultaneously, enabling broader therapeutic applications, including complex diseases such as cancer, cardiovascular conditions, and neurodegenerative disorders. siRNA is known for its specificity in gene silencing, directly degrading messenger RNA (mRNA) to prevent protein synthesis. This precision enables targeted therapeutic interventions. Antisense RNA technology employs a complementary strand to inhibit mRNA translation, offering unique therapeutic interventions for gene expression regulation. Advances in antisense oligonucleotides (ASOs) are enhancing their stability and reducing side effects, propelling clinical trials into late-stage developments and potential new market entries. siRNA offers unmatched specificity, which is ideal for precise genetic targeting, making it favorable for treating rare genetic disorders. miRNA provides a broad impact by regulating multiple genes, suitable for complex, multifactorial diseases such as cancer.

• Application: Boosting applications of antisense & RNAi therapeutics in oncology due to targeting cancer-specific mutations

  Oncology represents the most critical segment due to the high prevalence and mortality rate of cancer globally. The use of antisense and RNAi therapeutics in oncology encompasses a variety of cancers, including breast, lung, prostate, and colorectal cancer. These therapies primarily focus on gene silencing, targeting cancer-specific mutations, and overcoming drug resistance. Genetic disorders constitute a crucial area due to the often severe and life-threatening nature of these conditions. Antisense and RNAi therapeutics can modify specific genetic abnormalities, offering substantial therapeutic potential for genetic disorders treatment. The complexity of Alzheimer's, Parkinson's, and Huntington's diseases underscores the necessity for advanced therapeutic options. Antisense and RNAi therapeutics target specific genetic mutations or proteins implicated in neurodegenerative diseases, slowing disease progression and improving patient quality of life. Antisense and RNAi therapeutics target underlying genetic contributors to cardiovascular diseases, addressing conditions such as hypercholesterolemia, atherosclerosis, and heart failure. Respiratory disorders, including asthma, chronic obstructive pulmonary, and cystic fibrosis disease, represent significant health burdens. Antisense and RNAi therapeutics can effectively target underlying genetic and molecular causes of these disorders. Renal diseases, including chronic kidney disease and polycystic kidney disease, require innovative treatments due to limited existing options. Antisense and RNAi hold the potential for disease modification at the genetic level.

The porter's five forces analysis offers a simple and powerful tool for understanding, identifying, and analyzing the position, situation, and power of the businesses in the Antisense & RNAi Therapeutics Market. This model is helpful for companies to understand the strength of their current competitive position and the position they are considering repositioning into. With a clear understanding of where power lies, businesses can take advantage of a situation of strength, improve weaknesses, and avoid taking wrong steps. The tool identifies whether new products, services, or companies have the potential to be profitable. In addition, it can be very informative when used to understand the balance of power in exceptional use cases.

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Antisense & RNAi Therapeutics Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Antisense & RNAi Therapeutics Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

• Sirnaomics Ltd. showcased innovative galAhead muRNA technology at the 2024 OPT congress in Boston

  Sirnaomics Ltd., a biopharmaceutical company in advanced RNAi therapeutics, spotlighted its GalAhead technology-based programs at the 2024 OPT Congress in Boston, USA. The presentation emphasized their innovative dual-targeted-GalNAc design and muRNA platform drug candidates. This system utilizes GalNAc ligands for targeted delivery to liver hepatocytes, offering potential treatments for liver-related diseases. The unique muRNA structure comprises duplexes with two antisense strands, complementary adapter strands, and specific labile spots that cleave post-delivery into individual RNAi triggers targeting respective genes. [Published On: March 12, 2024]

• Ribocure Pharmaceuticals AB and Boehringer Ingelheim International GmbH partner to develop innovative RNAi-based treatments

  Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals AB entered into a collaboration with Boehringer Ingelheim International GmbH to develop treatments for nonalcoholic or metabolic dysfunction-associated steatohepatitis. This partnership combined Ribocure Pharmaceuticals AB's expertise in small interfering RNA (siRNA) therapeutics with Boehringer Ingelheim International GmbH's dedication to addressing cardiovascular, renal, and metabolic diseases (CRM). Ribocure Pharmaceuticals AB's RIBO-GalSTAR platform facilitates the development of RNAi therapeutics that target and silence disease-causing genes in hepatocytes. [Published On: March 01, 2024]

• Shanghai Argo Biopharmaceutical Co., Ltd. partnered with Novartis AG in a Landmark USD 4.165 Billion deal to advance RNAi therapeutics for cardiovascular diseases

  Shanghai Argo Biopharmaceutical Co., Ltd., a biotechnology company in next-generation RNAi therapeutics, announced exclusive license and collaboration agreements with Novartis Pharma AG. The agreement provides Novartis AG an exclusive license outside China to develop and commercialize a Phase 1/2a cardiovascular program. These assets were developed using Shanghai Argo Biopharmaceutical Co., Ltd.'s advanced RNAi platform. [Published On: January 07, 2024]

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Antisense & RNAi Therapeutics Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

The report delves into recent significant developments in the Antisense & RNAi Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Alnylam Pharmaceuticals, Inc., Amarna Therapeutics BV, Arbutus Biopharma Corporation, Arrowhead Pharmaceuticals, Inc., AstraZeneca plc, Benitec Biopharma Limited, Carisma Therapeutics Inc., Evox Therapeutics Ltd, GenScript Biotech Corporation, Ionis Pharmaceuticals, Inc., Novo Nordisk A/S, Regenxbio Inc., Sanofi S.A., Silence Therapeutics plc, Sirnaomics, Inc., Viridian Therapeutics, Inc., and Wave Life Sciences Ltd.

This research report categorizes the Antisense & RNAi Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Technology
  • Antisense RNA
  • RNA Interference
    • miRNA
    • siRNA
• Route of Administration
  • Intra-dermal Injections
  • Intraperitoneal Injections
  • Intravenous Injections
  • Pulmonary Delivery
  • Topical Delivery
• Application
  • Cardiovascular Diseases (CVDs)
  • Genetic Disorders
  • Infectious Diseases
  • Neurodegenerative Disorders
  • Oncology
  • Renal Diseases
  • Respiratory Disorders
• End User
  • Hospitals:
  • Pharmaceutical & Biotechnology Companies
  • Research & Academic Institutes
  • Specialty Clinics

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

1. Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
2. Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
3. Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
4. Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
5. Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.

1. What is the current market size and projected growth?
2. Which products, segments, applications, and regions offer promising investment opportunities?
3. What are the prevailing technology trends and regulatory frameworks?
4. What is the market share and positioning of the leading vendors?
5. What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?